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diagnostic accuracy, with a sensitivity and specificity of 69% and
92%, respectively. Sensitivity increased to 90% when patients on
glucocorticoids were excluded. The number of vascular segments with
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Abstract: Giant cell arteritis (GCA) is the most frequent form of
vasculitis in persons older than 50 years. Cranial and systemic large
vessels can be involved. [18F] fluorodeoxyglucose (FDG) positron
emission tomography (PET)/computed tomography (CT) is increasingly
used to diagnose inflammation of the large arteries in GCA. Unfortu-
nately, no consensus exists on the preferred scoring method. In the
present study, we aim to define the optimal FDG PET/CT scoring
method for GCA diagnosis using temporal artery biopsy and clinical
diagnosis as the reference method.
FDG PET/CT scans of GCA patients (12 glucocorticoid-naive, 6 on
glucocorticoid treatment) and 3 control groups (inflammatory, athero-
sclerotic, and normal controls) were evaluated. We compared 2 qual-
itative visual methods (i.e. (1a) first impression and (1b) vascular uptake
versus liver uptake) and 4 semiquantitative methods ((2a) SUVmax
aorta, (2b) SUVmax aorta-to-liver ratio, (2c) SUVmax aorta-to-
superior-caval-vein ratio, and (2d) SUVmax aorta-to-inferior-caval-
vein ratio). FDG uptake pattern (diffuse or focal) and presence of
arterial calcifications were also scored.
Diagnostic accuracy of the visual method vascular versus liver
uptake (1b) was highest when the cut-off point ‘‘vascular uptake higher
than liver uptake’’ (sensitivity 83%, specificity 91%) was used. Sen-
sitivity increased to 92% when patients on glucocorticoids were
excluded from the analysis. Regarding the semiquantitative methods,
the aorta-to-liver ratio (2b) with a cutoff of 1.03 had the highest, PhD, Kornelis S. est, MD,
and Riemer H.J.A. Slart, MD, PhD
diffuse FDG uptake pattern was significantly higher in GCA patients
without glucocorticoid use compared with all control patient groups.
CRP was not significantly different between positive and negative FDG
PET scans in the GCA group.
Visual vascular uptake higher than liver uptake resulted in the
highest diagnostic accuracy for the detection of GCA, especially in
combination with a diffuse FDG uptake pattern. Of the semiquantitative
methods, the aorta-to-liver SUVmax ratio (cutoff point¼ 1.03) had the
highest diagnostic accuracy. The diagnostic accuracy increased when
patients using glucocorticoids were excluded from the analyses.
(Medicine 94(37):e1542)
Abbreviations: CRP = C-reactive protein, FDG PET LDCT =
[18F]fluorodeoxyglucose positron emission tomography low dose
CT, GCA = giant cell arteritis, ICV = inferior caval vein, ROC =
receiver-operating characteristic, ROI = region of interest, SCV =
superior caval vein, SUV = standardized uptake value.
INTRODUCTION
G iant cell arteritis (GCA) is the most common form ofvasculitis in persons older than 50 years. The aorta and the
main branches of the aorta are mostly affected. The name GCA
is derived from the giant cells that are typically found in
histological specimens.1 GCA rarely occurs in people under
the age of 50 and women are 2 to 3 times more often affected
than men.2 The incidence is highest in northern Europe and
reaches 20–30 per 100,000 in the population older than 50 in
Sweden.3 In 40% of GCA cases, polymyalgia rheumatica
coexists.4
In the past, GCAwas often named temporal arteritis, due to
the involvement of the temporal artery and the related typical
cranial symptoms. In the last 2 decades, it became clear that 2
overlapping variants of the disease can be distinguished: cranial
and systemic GCA.5,6 In GCA, inflammation of the vessel walls
results in intimal hyperplasia that can occlude blood vessels
which might result in new headache, visual loss, stroke, and
limb and jaw claudication.2 In systemic GCA, the inflammatory
state may cause fatigue, fever, weight loss, and malaise.5
Longstanding undiagnosed GCA of the aorta predisposes
patients to aneurysms and aortic dissection.7 Standard treatment
of GCA consists of high-dose glucocorticoids.1
GCA is diagnosed when patients fulfil 3 out of 5 ACR 1990
classification criteria.8 Amajor drawback of these criteria is that
they are mainly based on symptoms of cranial GCA. For cranial
GCA, the temporal artery biopsy is often positive. This invasiveensitivity; only 43% of temporal artery
in GCA patients who present without
ms.5 For systemic GCA a standardized,
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Sex (female/male) 9/3 6/0 15/3 14/5 14/2
Age 69.6 9.7 69.4 3.9 67.7 7.7 69.0 8.8 58.8 7.3
TAB (Pos/Neg/ND) 5/2/5 2/1/3 NA NA NA
ACR (Pos/Neg) 7/5 5/1 NA NA NA
CRP (range) 55 (20–147) 8 (5–59) 69 (18–176) 11 (9–14) 5 (5–16)
Glucose (mmol/L, range) 6.2 (5.3–7.1) 5.8 (4.5–8.6) 6.1 (2.9–10.8) 5.9 (4.9–9.8) 5.8 (5.0–8.0)
Use of statins 5 1 3 8 1
Liver/kidney disturbances 0/0 0/1 6/7 5/3 2/2
Visual FDG uptake compared
with liver (range)
35 (19–40) 22 (11–37) 12 (6–16) 13 (5–27) 12 (10–17)
Number of diffuse segments (range) 13 (5–14) 4 (0–13) 0 (0–2) 0 (0–9) 0 (0–5)
Calcification score (range) 14 (0–33) 12 (3–21) 12 (2–46) 22 (6–34) 2 (0–8)
ACR¼American Rheumatology Society criteria for the classification of GCA; Atherosclerosis¼ control group with calcifications on PET/CT;
CI¼ 95% confidence interval. NA¼ not applicable, ND¼ not done, Neg¼ negative, Normal¼ control group without an elevated CRP, without
y. G
an
Stellingwerff et al Medicine  Volume 94, Number 37, September 2015reproducible diagnostic tool is lacking. Histological specimens
of the aorta are impossible to obtain unless a vascular calamity
requires aortic surgery.9
With the use of [18F]fluorodeoxyglucose (FDG)
positron emission tomography (PET), it is possible to image
glucose metabolism in the vessels.10 FDG is taken up by cells
with a high metabolic rate, which makes it possible to identify
the focus of inflammation. FDG PET may therefore diagnose
GCA at an earlier stage than MR angiography (MRA) or CT
angiography (CTA).1 In previously published studies, FDG-
PET was found to have an added value for the initial diagnosis
in patients with nonspecific symptoms (fever without known
cause) to identify an area for biopsy, to evaluate the extent of
the disease, and to evaluate the success or failure of therapy.11–
13 However, especially for the diagnosis of GCA based on
FDG-PET both visual and semiquantitative methods have been
published. In 2003, Meller et al14 were the first to make the
comparison between vascular uptake and liver uptake, using a
4-point scale (grade 0: no uptake, grade I: uptake lower than
liver, grade II: similar to liver, and grade III: higher than liver).
In several articles, vascular uptake similar to or higher than
liver uptake was defined as a scan positive for GCA.18–21 It has
been shown that there is an association between arterial FDG
uptake and computed tomography (CT) derived vascular
calcification score.22 This indicates that it is important to
distinguish focal (atherosclerotic) and diffuse (vasculitis)
FDG uptake.23,24
In 2008, Hautzel et al15 proposed the use of the aorta-to-
liver standardized uptake value (SUV) ratio. First, the FDG
uptake in the aorta and in the liver is quantified by constructing
regions of interest (ROIs) on the PET image, followed by the
aorta-to-liver SUV ratio calculation. A ratio >1 supports
the diagnosis of GCA.15 Theoretically, this should make the
PET/CT more suitable for clinical use, since only anatomical
knowledge is needed. However, it is a time-consuming method
and it is doubtful whether this method has added value to the
4-point scale.
calcifications on PET/CT, Pos¼ positive, TAB¼ temporal artery biops
patients on glucocorticoid treatment, inflammation¼ control group withIn 2014, Besson et al16 reported on a semiquantitative
approach in GCA. They reported that the aortic to venous blood
pool SUV max ratio outperformed the lung and liver ratios.16
2 | www.md-journal.comSummarized, different methods for assessment of the
inflamed aorta have been described and there is no preferred
method yet. In a recent metaanalysis the different methods were
compared for diagnostic performance and their advantages and
limitations. A drawback of this metaanalysis was that the
studies were very heterogeneous with respect to patients,
methods, and healthy controls, and therefore hard to compare.25
The primary aim of our study was therefore to evaluate all
relevant scoring methods for the diagnosis of GCA using FDG
PET/CT in a group of well classified GCA patients compared
with 3 different control groups. In order to increase the diag-
nostic yield, the FDG uptake pattern was also studied, and
finally the FDG uptake was correlated with the degree of
calcification on low-dose CT (LDCT).
METHODS
This retrospective study was performed at the University
Medical Center of Groningen (UMCG). Since our study was
performed retrospectively, we were relieved by the ethics
committee of our hospital from obtaining informed consent.
Laboratory and clinical data were retrieved from the
hospital’s electronic patient system. C-reactive protein (CRP)
was used as a marker of inflammation as erythrocyte sedimen-
tation rate (ESR) was not always measured. The following
clinical data were recorded: temporal artery biopsy findings,
whether the patient met the ACR criteria for GCA, and the use
and dose of glucocorticoids and/or statins.
Patient Group
All GCA patients who underwent a FDG PET/LDCT scan
between November 2009 and December 2012 were retrospec-
tively selected from the database of our hospital. Patients either:
fulfilled the ACR classification criteria for GCA, had a positive
temporal artery biopsy, or had a clinical diagnosis of GCA
(typical clinical and laboratory picture, response to steroids,
typical findings on ultrasound, anterior ischemic optic neuritis),
CAa¼GCA patients without glucocorticoid treatment. GCAb¼GCA
elevated CRP.which could not be explained otherwise and which held true
during at least 1 year of follow-up. Patients that underwent
vascular surgery (e.g., vascular endoprosthesis) or had focal
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
minimized. In the liver, we projected the ROI on the right
lobe to reduce the chance of including the various veins and
arteries running through the liver.
<10
TABLE 2. Visual Grades of Vascular FDG Uptake14
Grade 0 No vascular FDG uptake
Medicine  Volume 94, Number 37, September 2015 FDG PET/CT in Giant Cell Arteritisinstead of diffuse FDG uptake in the liver were excluded. Low-
dose glucocorticoid treatment (<10mg/day) initiated before the
FDG PET/CT scan was allowed (6 out of 18 patients) (Table 1).
Patients were regarded as steroid-naive when they had not
received treatment for a period of 30 days before FDG PET/
CT. The GCA group was divided into patients either using or not
using glucocorticoids.
Control Groups
We chose controls to exclude the effect of inflammation
and atherosclerosis on FDG uptake. CRP has a direct proin-
flammatory effect on endothelial cells26 and hepatic cells,
which may result in increased arterial FDG uptake. The pre-
sence of atherosclerotic plaques can also cause an increased
arterial FDG uptake.22
Inflammatory Controls
The first control group existed of patients with an elevated
CRP without being diagnosed as having GCA. We selected this
group by searching the nuclear medicine department’s database
for ‘‘fever of unknown origin’’ as one of the primary reasons for
FDG PET scanning. Out of 50 patients, 18 patients were
selected who were matched for age, sex, and CRP with the
GCA group.
Atherosclerotic Controls
Regarding the second control group, we selected patients
with a vascular calcification score higher than 222 (method-
ology, see Figure 1) on the low-dose CT (LDCT). This was
executed by randomly reviewing scans that were performed
from 2010 and onward. Patients were matched for age and sex
with the GCA group.
Normal Controls
As a final control group, patients without inflammation and
no vascular calcifications on LDCT were selected. We ran-
domly reviewed scans of patients older than 50 from 2010 and
onward without any vascular calcifications. Due to difficulties
in finding older patients without calcifications on the scan, this
group was only matched for sex.
Scanning Procedure
All FDG PET LDCT scans were performed on a Biograph
mCT camera system (Siemens Medical Systems, Knoxville,
TN) and were performed according to a standardized protocol
[EANM guidelines, 2010–2011]. In short, after fasting for at
least 4 hours, whole-body (from head to knees) or total-body
(from head to toes) PET scans were acquired 60 (5) min after
FIGURE 1. Calcification score.22 Plaque score 0: no calcification, 1:
calcification.intravenous injection of 3MBq/kg FDG. A low-dose CT scan
was acquired prior to the PET-emission scan for attenuation
correction and anatomic localization. FDG uptake was
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.quantified with the maximal standardised uptake value (SUV-
max) using the EANM Research Limited (EARL) reconstruc-
tion techniques.27
Scoring Procedure
Two nuclear medicine physicians (AG, RS) were blinded
to patient data when scans were visually interpreted.
FDG Uptake
We applied 2 qualitative visual methods. In method 1a, the
PET/CT scan was judged on first impression (i.e., gestalt) as
normal or vasculitis, depending on whether FDG uptake was
found in the large arteries. This judgment was based on expert
opinion of experienced nuclear medicine physicians.10 In
method 1b, 14 vascular segments (i.e., the aortic arch, the
ascending, descending and abdominal aorta, and both vertebral,
carotid, subclavian, iliac, and femoral arteries) were scored by
the method as previously described by Meller et al14 (see
Table 2). Briefly, the visual scoring system is as follows: grade
0 is no vascular FDG uptake, grade I is vascular FDG uptake
less than liver, grade II is vascular FDG uptake similar to liver,
and grade III is vascular FDG uptake higher than liver FDG
uptake. Median and range of the sum scores (max sum score is
42) on FDG uptake per patient are presented in the results
section. Interobserver variability between both readers
was evaluated.
With the semiquantitative methods (2a–d), ellipsoids
were placed on the vascular branches to determine maximal
standard uptake values (SUVmax) within the ROI by 1
observer. In method 2a (SUVmax aorta), the SUVmax of
the aorta (subdivided in the SUVmax of the aortic arch, the
ascending, descending, and abdominal aorta) was determined.
In method 2b (SUVmax ratio aorta-to-liver), method 2c
(SUVmax ratio aorta-to-superior-caval-vein (SCV)), and
method 2d (SUVmax ratio aorta-to-inferior-caval-vein
(ICV)), the SUVmax of the aorta was compared with back-
ground FDG uptake (SUVmax of the liver, SCV, and the
ICV, respectively). We aimed to draw large ROIs around the
majority of the target vascular structure, while the chance of
including surrounding FDG uptake within the ROI was
%, 2: 10–25%, 3: 25–50%, and 4:>50%of the vessel affected byGrade I Vascular FDG uptake less than liver FDG uptake
Grade II Vascular FDG uptake equal to liver FDG uptake
Grade III Vascular FDG uptake higher than liver FDG uptake
www.md-journal.com | 3
TABLE 3. Sensitivity and Specificity on Various Cut-Off Points for Visual Scoring
Grade II Group True Test False Test Sensitivity (%) Specificity (%)
GCA (steroid) 12 (6) 0 (0) 100 (100)
Inflammation 12 6 67
Atherosclerosis 7 12 37
Normal 8 8 50
Diffuse
Grade II
Group True Test False Test Sensitivity (%) Specificity (%)
GCA (steroid) 12 (4) 0 (2) 100 (89)
Inflammation 16 2 88
Atherosclerosis 15 4 79
Normal 12 4 75
Grade III Group True Test False Test Sensitivity (%) Specificity (%)
GCA (steroid) 11 (4) 1 (2) 92 (83)
Inflammation 17 1 94
Atherosclerosis 15 4 79
Normal 16 0 100
Diffuse
Grade III
Group True Test False Test Sensitivity (%) Specificity (%)
GCA (steroid) 10 (2) 2 (4) 83 (67)




Normal 16 0 100
True test is either true positive (for GCA group) or true negative (for control groups). False test is either false negative (for GCA group) or false
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When FDG uptake was present in the vascular segment, we
evaluated whether the uptake was diffuse (homogeneous) in the
vessels or focal (heterogeneous). Median and range of the
number of segments with diffuse uptake were quantified
(max score is 14). Interobserver variability between both read-
ers was evaluated.
Calcification on Low-Dose CT
The degree of calcification was visually scored according
to the classification system of Rominger22 (see Figure 1).
Briefly, vascular score was 0: no calcification, 1: <10%, 2:
10–25%, 3: 25–50%, and 4: >50% of the vessel affected by
calcification. Median and range of the sum scores on calcifica-
tion (max sum score is 56) per patient were quantified. Inter-
observer variability between both readers was evaluated.
Statistics
Data are presented as mean ( SD) or as median (range)
for normally distributed and nonnormally distributed data,
respectively. Interobserver reliability between both readers
Specificity is displayed for all control groups separately. Grade II: FDG u
uptake in at least 1 vessel is higher than FDG uptake in the liver. Diffuse:
Patient presenting after chemotherapy for non-Hodgkin lymphomawas evaluated using Cohen’s Kappa for categorical data and
intraclass correlation coefficient (ICC; 2-way mixed effects
model, single measures, absolute agreement) for continuous
4 | www.md-journal.comdata. Values of <0.4, between 0.4 and 0.75, and >0.75 were
considered to represent poor, fair to good, and excellent
agreement, respectively.
Background FDG uptake (SUVmax of the liver, SCV, or the
ICV) was compared between groups. Subsequently, the ratios
between the SUVmax in the vessel wall and background were
compared. ROC curves were reconstructed and analyzed to
determine the optimal cutoff points and corresponding sensitivity
(GCA group) and specificity (control groups) for each method.
Diagnostic accuracy is defined as the average of the sensitivity
and specificity of each method. Subanalyses for GC-treated and
nontreated GCA patients were performed to determine the influ-
ence of glucocorticoid treatment in GCA patients on diagnostic
performance. Statistical analysiswas performed using IBMSPSS
Statistics 20 (SPSS Inc, Chicago, IL).
RESULTS
A total of 71 scans were analyzed. Patient characteristics
and sum scores on FDG uptake grade, uptake pattern, and
calcification score are presented in Table 1.
e in at least 1 vessel is similar to FDG uptake in the liver. Grade III: FDG
G uptake in the vascular segment of either grade II or grade III is diffuse.Visual Methods of FDG Uptake
The uptake of the vascular regions was significantly higher
in both GCA groups compared with the control groups
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. SUVmax SD of the Various Backgrounds and the Segments of the Aorta
GCAa (10) GCAb (6) Inflammation (18) Atherosclerosis (19) Normal (16)
Liver 3.01 0.52 4.20 1.32 3.33 1.13 3.28 0.80 2.98 0.74
ICV 2.26 0.73 2.55 0.95 2.21 0.76 2.01 0.54 1.86 0.48
SCV 2.13 0.45 2.27 0.67 2.06 0.72 1.93 0.47 1.88 0.48
Ascendens 3.17 0.64 3.39 0.57 2.41 0.63 2.33 0.48 2.19 0.50
Arcus 2.87 0.62 3.37 0.27 2.40 0.71 2.52 0.66 2.16 0.57
Descendens 3.32 0.77 3.74 0.40 2.63 0.72 2.50 0.65 2.37 0.55
Abdominal 3.67 1.21 3.97 0.82 2.69 0.77 2.64 0.73 2.27 0.59
MaxAorta 3.83 1.10 4.04 0.77 2.89 0.79 2.82 0.76 2.45 0.57
GCAa¼GCA patients without glucocorticoid treatment; GCAb¼GCA patients on glucocorticoid treatment; ICV¼ inferior caval vein; Max-
Aorta¼ highest SUVmax of the segments of the aorta; SCV¼ superior caval vein; SD¼ standard deviation; SUVmax¼maximal standard FDG
Medicine  Volume 94, Number 37, September 2015 FDG PET/CT in Giant Cell Arteritis(P< 0.05). The uptake of vascular regions did not differ sig-
nificantly between the various control groups.
For method 1a, overall judgement based on expert opinion,
sensitivity was 56% and specificity was 98%. Sensitivity
increased to 75% when excluding patients with glucocorticoid
treatment from the analysis. The interobserver agreement for
this method was very high (Cohen’s kappa ¼ 0.94).
The highest diagnostic accuracy in method 1b was
achieved by defining a scan positive when an arterial structure
revealed a higher visual uptake than liver (grade III) (sensitivity
83%, specificity 91%, sensitivity raised to 92% when patients
on glucocorticoid treatment were excluded, specificity
remained 91%). When FDG uptake similar to liver (Grade
II) was also judged as positive, sensitivity was 100%, but
specificity dropped to 51%. In Table 3, the occurrence of
vascular FDG uptake similar to and higher than liver FDG
uptake of the various control groups is shown. The interobserver
agreement on the sum scores of visual FDG uptake was very
high (ICC¼ 0.99).
Semiquantitative Analysis
The FDG uptake of the vascular regions was significantly
higher in both GCA groups than the control groups (P< 0.05).
The FDG uptake of vascular regions did not differ significantly
between the various control groups. The background FDG
uptake did not significantly differ between the GCA and control
groups (see Table 4). Table 5 shows the average SUVmax ratio
per semiquantitative method and patient group. All semiquan-
titative methods had good diagnostic accuracy (see Table 6).
uptake value in a region of interest.
Missing value due to port-a-cath.The FDG uptake in all ROIs was higher in GCA patients
receiving glucocorticoids than in those not receiving glucocor-
ticoids; however, the differences were not significant.
TABLE 5. SUVmax Ratios SD. SUVmax Aorta Compared With S
SUV Ratio (n) GCAa (10) GCAb (10) Infla
Liver 1.25 0.21 1.00 0.17 0.
ICV 1.72 0.23 1.69 0.39 1.
SCV 1.79 0.26 1.90 0.56 1.
GCAa¼GCA patients without glucocorticoid treatment; GCAb¼GC
SCV¼ superior caval vein; SD¼ standard deviation.
Missing value due to port-a-cath.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Method 2a (SUVmax Aorta)
When only taking the FDG uptake in the aorta into
account, the optimal cutoff value was a SUVmax of 3.12. As
presented in Table 6, this yields a sensitivity of 83% and a
specificity of 73%. In the subanalysis, the diagnostic accuracy
was higher in GCA patients with glucocorticoid treatment
(sensitivity 100%, specificity 83%) than in those without (sen-
sitivity 83%, specificity 62%).
Method 2b (SUVmax Aorta-to-Liver Ratio)
When dividing the FDG uptake in the aorta with the
background FDG uptake in the liver, the optimal cutoff value
was a SUVmax ratio of 1.03. As presented in Table 6, this yields
a sensitivity of 72% and a specificity of 92%. In the subanalysis,
the diagnostic accuracy was lower in the GCA patients with
glucocorticoid treatment (sensitivity 67%, specificity 62%) than
in those without (sensitivity 92%, specificity 92%).
Method 2c (SUVmax Aorta-to-SCV Ratio)
When dividing the FDG uptake in the aorta with the FDG
uptake in the SCV, the optimal cut-off value was a SUVmax
ratio of 1.65. As presented in Table 6, this yields a sensitivity of
72% and a specificity of 92%. When looking at the subanalysis,
the diagnostic accuracy was lower in the GCA patients with
glucocorticoid treatment (sensitivity 67%, specificity 92%) than
in those without (sensitivity 75%, specificity 96%).
Method 2d (SUVmax Aorta-to-ICV Ratio)
When dividing the FDG uptake in the aorta with the FDG
uptake in the ICV, the optimal cutoff value was a SUVmax ratio
of 1.60. As presented in Table 6, this yields a sensitivity of 67%
UVmax of the Background
mmation (18) Atherosclerosis (19) Normal (16)
90 0.18 0.85 0.14 0.83 0.12
35 0.24 1.39 0.25 1.33 0.24
45 .028 1.43 0.16 1.32 0.16
A patients on glucocorticoid treatment; ICV¼ inferior caval vein;
www.md-journal.com | 5
TABLE 6. AUCs, Optimal Cut-Off Values and Corresponding Sensitivity and Specificity of the Semiquantitative Methods
All Patients AUC (CI) Cut-Off Value Sensitivity Specificity
Method 2a (no background) 0.82 (0.71–0.93) 3.12 83% 73%
Method 2b (liver) 0.88 (0.79–0.97) 1.03 72% 92%
Method 2c (ICV) 0.83 (0.72–0.94) 1.60 67% 86%
Method 2d (SCV) 0.82 (0.69–0.96) 1.65 72% 92%
Without GC Treated AUC (CI) Cut-Off Value Sensitivity Specificity
Method 2a (no background) 0.79 (0.65–0.93) 2.75 83% 62%
Method 2b (liver) 0.94 (0.88–1.00) 1.03 92% 92%
Method 2c (ICV) 0.87 (0.78–0.96) 1.48 92% 73%
Method 2d (SCV) 0.85 (0.71–1.00) 1.72 75% 96%
Only GC Treated AUC (CI) Cut-Off Value Sensitivity Specificity
Method 2a (no background) 0.88 (0.79–0.97) 3.58 100% 83%
Method 2b (liver) 0.75 (0.59–0.92) 0.85 67% 62%
Method 2c (ICV) 0.75 (0.51–0.99) 1.62 67% 88%
Method 2d (SCV) 0.76 (0.50–1.00) 1.65 67% 92%
erio
GCA
Stellingwerff et al Medicine  Volume 94, Number 37, September 2015and a specificity of 86%. When looking at the subanalysis, the
diagnostic accuracy was lower in the GCA patients with
glucocorticoid treatment (sensitivity 67%, specificity 88%) than
in those without (sensitivity 92%, specificity 73%).
When comparing the 4 above-mentioned semiquantitative
methods, the SUVmax aorta-to-liver ratio had the highest AUC
value and therefore the highest diagnostic accuracy (Figure 2,
Table 6). The diagnostic accuracy was higher when patients on
glucocorticoid treatment were excluded, except in Method 2a
(SUVmax aorta). Optimal cutoff point for the aorta-to-liver
ratio was 1.03, with a specificity of 92%. Sensitivity is 69%, or
90% when patients on glucocorticoid treatment were excluded.
AUC¼ area under the curve; CI¼ 95% confidence interval; ICV¼ inf
treatment excluded; SCV¼ superior caval vein; Without GC treated¼FDG Uptake Pattern
As illustrated in Table 1, the number of vascular segments
with diffuse FDG uptake pattern was significantly higher in
FIGURE 2. ROC curve on the SUVmax of the aorta (dotted), aorta-to-
inferior-caval-vein (dashed).
6 | www.md-journal.comGCA patients without glucocorticoid use compared with all
control patient groups (P< 0.05). The interobserver reliability
on the number of diffuse segments was very high (ICC¼ 0.99).
Examples are given in Figures 3 and 4.
Calcification on Low-Dose CT
Table 3 shows that the majority of patients from
the atherosclerosis control group were assigned as false
positive, especially when diagnosed only on the visual arter-
ial FDG uptake versus liver FDG uptake (Grade II: 12 out of
19, Grade III: 4 out of 19), without taking the FDG uptake
pattern into account. When the FDG uptake pattern is taken
into account, few patients are regarded false positive (Grade
r caval vein; Only GC treated¼GCA group not receiving glucocorticoid
group receiving glucocorticoid treatment excluded.II: 4 out of 19, Grade III: 1 out of 19). The interobserver
reliability on the calcification sum score was very high
(ICC¼ 0.99).
liver (solid), aorta-to-superior-caval-vein (dash-dot), and aorta-to-
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. PETscan of a patient with large vessel vasculitis. Diffuse
Medicine  Volume 94, Number 37, September 2015 FDG PET/CT in Giant Cell ArteritisDISCUSSION
This is the first study to compare both visual as semi-
quantitative methods in judging FDG PET/CT scans in defined
groups of GCA patients. In addition, the vascular FDG uptake
on FDG PET/CT scans of GCA patients was compared with 3
different control groups, including an atherosclerosis control
group, using the same methods. Main findings were that visual
vascular FDG uptake higher than liver resulted in the highest
diagnostic accuracy for the detection of GCA, especially in
combination with a diffuse FDG uptake pattern. An aorta-to-
liver SUVmax ratio higher than 1.03 revealed the highest
FDG uptake higher than liver FDG uptake (grade III) is visible in the
carotid arteries, the subclavian arteries, and the ascending aorta.diagnostic accuracy as the semiquantitative method. The diag-
nostic accuracy increased when patients using glucocorticoids
were excluded from analysis.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.The highest diagnostic power to diagnose GCA is achieved
when arterial wall FDG uptake is higher than liver by
visual evaluation.
Several methods have been described to quantify FDG
uptake in large vessel vasculitis. In 2003,Meller et al14 were one
of the first to use the comparison between liver FDG uptake and
arterial FDG uptake, using a 4-point scale. In several other
publications, arterial FDG uptake equal to liver FDG uptake and
also higher than liver FDG uptake was assigned as positive for
GCA.18–20,28 Our results indicate that specificity will drop to
51% when grade II FDG uptake (i.e., equal to liver) is qualified
as positive. Based on our results, only scans showing higher
arterial FDG uptake than liver FDG uptake (grade III) should be
assigned as positive for GCA. More recently, 3 studies were
published investigating different quantitative scoring methods.
Hautzel et al15 used the method SUVmax aorta-to-liver ratio
and a ratio >1 supported the diagnosis of GCA. Our results are
in line with the findings of this study, since our highest
diagnostic power was found for a cutoff SUVmax ratio value
FIGURE 4. PET scan of a patient with a malignancy in the left
hemi-thorax and without large vessel vasculitis. Minimal (blood
pool) FDG uptake is seen in the large arteries.of 1.03. Besson et al16 found that the caval vein was superior to
the liver and the lung as background for the vascular FDG
uptake. Prieto-Gonzalez et al17 studied 32 GCA patients
www.md-journal.com | 7
positive on temporal artery biopsy, of whom 17 were on
glucocorticoid treatment (<4 days), and used 20 controls. In
that study the authors used the arterial SUVmax without taking
the background FDG uptake into account.17
In the literature, the diagnostic power of FDG PET/CT in
GCA has often been discussed. In various studies, a low
sensitivity was found ranging from 60 to 73%.29,30 However,
this could be due to the inclusion of patients on glucocorticoid
treatment. In a study of Lehmann et al,29 8 out of 20 patients
were on glucocorticoids, and in a study of Walter et al,30 17 out
of 26 patients were on glucocorticoids. In a metaanalysis of 6
studies in 2005, an overall sensitivity of 80% and specificity of
89% was shown which lowered when patients on immunosup-
pressive therapy were included.31 This is in line with our results;
we found that GCA patients on glucocorticoid treatment are
comparable to control patients. In the SUVmax aorta-to-liver
ratio, sensitivity increased from 69% to 90% when excluding
patients on glucocorticoid treatment. With the visual scoring
method, sensitivity increased from 83% to 92%.
We noticed that there was a trend to higher FDG uptake in
the liver in GCA patients receiving glucocorticoid treatment
compared with GCA patients not receiving glucocorticoids.
Recently, Besson et al16 reported that the aortic-to-blood-pool
ratio outperformed the aorta-to-liver ratios and Prieto-Gonzalez
et al17 found that the aorta-to-liver ratio had a much lower
discriminatory performance than the aorta SUVmax. They
concluded that the liver is not reliable to use as a background,
since FDG uptake was higher in GCA patients. However, both
studies included a relative large number of patients receiving
glucocorticoids (Besson: 9 out of 12 (75%), Prieto-Gonzalez: 17
out of 32 (53%)). In our study 33% (n¼ 6) of GCA patients were
on glucocorticoids and we clearly showed an increased liver
FDG uptake in these patients comparedwith GCA patients not
on steroid treatment (n¼ 12). This higher liver FDG uptake in
GCA patients on glucocorticoids (see Table 6) results in a lower
diagnostic accuracy of the SUVmax aorta-to-liver ratio.
It has been shown that a correlation exists between arterial
FDG uptake and arterial calcification score.22 Therefore, it is
important to distinguish focal (atherosclerosis) from diffuse
(vasculitis) FDG uptake.23,24 The use of statins may reduce the
FDG uptake in the atherosclerotic process32 and this could
therefore be a confounder in our study. However, the use of
statins between the atherosclerotic patient group and the GCA
group was not significantly different in our study (see Table 1).
The main difficulty in performing a study to evaluate the
diagnostic accuracy of the PET/CT scan in GCA is the lack of a
gold standard. Some studies take a positive temporal artery
biopsy as a gold standard, but not all TAB-positive patients have
aortic involvement. Other studies based the gold standard solely
on clinical findings. Differences in clinical findings could have
interfered with the outcome and comparability of these studies.
The advantage of our study is that we used the same group of
GCA patients and several different control groups to compare
the different scoring methods. A limitation of our study is that
we retrospectively selected the groups. A better way to test the
diagnostic accuracy of the FDG PET/CT would be to perform a
prospective study including patients suspected of having GCA.
Of interest, we found that the CRP level was not related to
FDG PET uptake, and that glucocorticoids increased both the
vessel wall and liver FDG uptake.
Stellingwerff et alCONCLUSION
FDG-PET/CT is an important imaging technique for diag-
nosing systemic GCA. Based on our results, a visual grading
8 | www.md-journal.commethod with an arterial FDG uptake higher than the liver FDG
uptake has the highest diagnostic accuracy for GCA. It is also
important to score the pattern of FDG uptake (focal vs. diffuse)
and to correct for the presence of atherosclerosis. When using
the semiquantitative methods, the best method is to calculate the
aorta-to-liver SUVmax ratio. Furthermore, the use of gluco-
corticoids results in a less reliable aorta-to-liver SUVmax ratio.
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